Rupam Manna/LinkedIn
Aug 17, 2026, 00:33
Rupam Manna: CELMoDs – Next-Generation Molecular-Glue Protein Degraders
Rupam Manna, Postdoctoral Student – DrNB Medical Oncology at National Board of Examinations, shared a post on X:
“CELMoDs: next-generation molecular-glue protein degraders.
By binding cereblon, CELMoDs redirect the CRL4–CRBN E3 ubiquitin ligase toward IKZF1 and IKZF3.
Their proteasomal degradation suppresses IRF4–MYC signalling, promotes myeloma-cell apoptosis and activates T and NK cells.
Key agents:
- Iberdomide – first FDA-approved CELMoD
- Mezigdomide – investigational in multiple myeloma
- Golcadomide – investigational in lymphoma
Remember the major class toxicities: neutropenia, infections, anaemia and thrombocytopenia.”
Stay updated with Hemostasis Today.
-
Aug 17, 2026, 00:38Jose Pedro Kessner: SEARCH Algorithm for Identifying Chronic Thromboembolic Phenotypes After Acute PE
-
Aug 17, 2026, 00:36Ryan Radecki: New Pulmonary Embolism Risk Categories Require Prospective Validation
-
Aug 17, 2026, 00:34Jeremy Judkins: Tesla Charging Stops May Help Reduce the Risk of Blood Clots During Long Road Trips
-
Aug 17, 2026, 00:32Chokri Ben Lamine: Septic Embolism in Hematology – Postgraduate Thread
-
Aug 16, 2026, 16:50Carlos Canelo-Aybar: First Steps Toward the New APS Diagnostic Guideline
-
Aug 16, 2026, 16:35Chaza Alaji: Is Prolonged aPTT Before Surgery a Bleeding Risk?
-
Aug 16, 2026, 16:13Juveriya Shaik: Awareness Study on Menstrual Delay Tablets and Risk of DVT
-
Aug 16, 2026, 16:05Bhaskar M.: Blood Bank – The Lifeline of Modern Healthcare
-
Aug 16, 2026, 15:54Oliver Weingärtner: The Care Transition Gap – Why LDL-C Control Is Lost After STEMI